Latest CBLL news and sentiment

Ceribell CFO Blumberg sells $36,534 in stock

Ceribell's CFO, Scott Blumberg, sold 1,521 shares worth $36,534 on August 21, 2026, to cover tax obligations related to restricted stock units. This transaction occurred as the company's shares traded near their 52-week high after a significant 109% gain over the past year. Despite a Q2 2026 loss per share, Ceribell reported a 33% increase in revenue, and analysts maintain positive outlooks with raised price targets due to the company's growth in seizure detection and new product development.

Ceribell president and CEO Chao Xingjuan sells $145,753 in stock

Ceribell President and CEO Chao Xingjuan sold 6,068 shares of company stock for $145,753 to cover tax obligations from RSU vesting. This transaction comes as Ceribell shares are near their 52-week high after a 109% return over the past year. The company recently reported strong Q2 2026 revenue growth and received FDA approval for expanded indications, leading analysts to raise price targets.

Ceribell (CBLL) CTO sells shares to cover RSU taxes

Ceribell, Inc.'s Chief Technology Officer, Raymond Woo, sold 1,979 shares of common stock at $24.02 per share on August 21, 2026. This transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). After the sale, Woo directly holds 194,729 shares, which includes shares acquired through an Employee Stock Purchase Plan.

Ceribell CEO sells $841,292 in company stock

Ceribell CEO Chao Xingjuan sold $841,292 worth of company stock in August 2026 through a Rule 10b5-1 trading plan. These sales occurred shortly after the stock reached a 52-week high, following a 108% gain over the past year. Despite a wider-than-expected Q2 loss, Ceribell reported a 33% revenue increase and positive analyst ratings, driven by growth in seizure detection and new product developments.

Ceribell CFO Scott Blumberg sells over $863k in company stock

Ceribell CFO Scott Blumberg sold over $863,000 worth of company stock in August 2026, following the exercise of stock options. The sales occurred when the stock was near its 52-week high, after a significant 108% return over the past year. These transactions, executed under a pre-arranged trading plan, left Blumberg directly holding 148,121 shares.

Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $24,750.00 in Stock

CeriBell CFO Scott Blumberg sold 990 shares of the company's stock for $24,750 on August 18th, and an additional 33,512 shares for $838,805 on August 19th, reducing his direct holdings. Despite these insider sales and a quarterly EPS miss, CeriBell's revenue exceeded expectations, and analysts generally maintain a "Moderate Buy" rating, although the average price target is below the current share price. The company specializes in newborn hearing screening devices and has seen some institutional investment changes.

Ceribell (CBLL) CFO sells 34,502 shares near $25 under 10b5-1 plan

Ceribell, Inc. (CBLL) CFO Scott Blumberg exercised stock options for 34,502 shares and subsequently sold all 34,502 shares at an average price of around $25 per share between August 18–19, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Blumberg directly holds 148,121 shares of common stock and 90,524 shares of stock options.

Scott Blumberg Sells 33,512 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell CFO Scott Blumberg sold 33,512 shares of the company's stock, valued at $838,805.36, decreasing his position by 18.45%. This sale follows a previous transaction of 990 shares. Despite the sell-off, analysts maintain a "Moderate Buy" consensus for CBLL, with a target price of $22.40, even as the company's shares traded down following a recent earnings report that missed EPS estimates but exceeded revenue forecasts.

CeriBell (NASDAQ:CBLL) CEO Sells 2,199 Shares

CeriBell CEO Xingjuan Chao recently sold 2,199 shares of the company's stock for $54,975, reducing her ownership by 0.27%. This sale is part of several recent transactions by the CEO, including a larger sale of 31,415 shares the following day. Despite these insider sales, analysts generally maintain a "Moderate Buy" rating for CBLL with an average price target of $22.40, even though the company reported a quarterly loss that missed estimates.

Ceribell (CBLL) CEO sells 33,614 shares in 10b5-1 trades

Ceribell (CBLL) President and CEO Chao Xingjuan sold a total of 33,614 shares of common stock on August 18-19, 2026, at prices around $25 per share, under a Rule 10b5-1 trading plan. The transactions included 31,415 shares sold on August 19 at a weighted average price of $25.03, and 2,199 shares sold on August 18 at $25.00. Xingjuan also reported an indirect holding of 369,088 shares through the ACP 2021 Trust, disclaiming beneficial ownership except for her pecuniary interest.

CeriBell (CBLL) Results Versus Estimates: EPS Falls Short of Its Estimate in the Current Update; Price Move: The Stock Records a 0.78% Decrease in the Latest Reading - Slow Growth Warning

Ceribell director Joseph Taylor sells $306,423 in company stock

Ceribell director Joseph Michael Taylor sold 13,095 shares of the company's common stock for $306,423. This transaction comes as Ceribell shares trade near their 52-week high, with the stock returning 97% over the past year. Despite recent revenue growth, the company reported a wider-than-expected loss per share in its Q2 2026 earnings.

Ceribell (CBLL) director sells 13,095 shares of common stock at $23.40

Ceribell (CBLL) director Joseph Michael Taylor sold 13,095 shares of common stock at $23.40 per share on August 13, 2026, totaling $306,423. Following this transaction, Taylor directly holds 48,478 shares of Ceribell common stock. This insider sale was reported via a Form 4 filing, indicating a moderate filing impact and negative sentiment.

CeriBell (CBLL) Stock Premium Rides High Margins Despite Deeper Losses

CeriBell (CBLL) stock saw a 10.4% increase after its Q2 earnings report, driven by headline growth in its high-margin medical device business, despite widened net losses. The company reported revenue of US$28.1m and a net loss of US$19.3m, with investors crediting progress in hospital penetration and product pipeline. Despite the premium 8x price-to-sales multiple compared to peers, concerns remain regarding increased operating expenses and execution risks for future revenue drivers.